Cycloastragenol

1. Cycloastragenol activates p38 MAPK signalling in worms.

   Model organisms

   Cycloastragenol extends lifespan and enhances stress resistance in Caenorhabditis elegans by inhibiting IIS pathway and activating p38 MAPK-mediated innate immunity · European journal of pharmacology · 10 Sep 2026

p38 MAPK signalling →

1. Cycloastragenol inhibits insulin/IGF-1 signalling in worms.

   Model organisms

   Cycloastragenol extends lifespan and enhances stress resistance in Caenorhabditis elegans by inhibiting IIS pathway and activating p38 MAPK-mediated innate immunity · European journal of pharmacology · 10 Sep 2026

Insulin/IGF-1 signalling →

1. Cycloastragenol decreases lipofuscin in worms.

   Model organisms

   Cycloastragenol extends lifespan and enhances stress resistance in Caenorhabditis elegans by inhibiting IIS pathway and activating p38 MAPK-mediated innate immunity · European journal of pharmacology · 10 Sep 2026

Lipofuscin →

1. Cycloastragenol improves locomotion in worms.

   Model organisms

   Cycloastragenol extends lifespan and enhances stress resistance in Caenorhabditis elegans by inhibiting IIS pathway and activating p38 MAPK-mediated innate immunity · European journal of pharmacology · 10 Sep 2026

1. Cycloastragenol extends lifespan in worms (+30.64% mean lifespan).

   Model organisms0.2 μM

   Cycloastragenol extends lifespan and enhances stress resistance in Caenorhabditis elegans by inhibiting IIS pathway and activating p38 MAPK-mediated innate immunity · European journal of pharmacology · 10 Sep 2026